Ethnicity and comorbidities in an overweight and obese multiethnic childhood cohort in Berlin

Dannemann, A.; Ernert, Andrea; Rücker, Petra; Bau, Anne-Madeleine; Martus, Peter; Krude, Heiko; Babitsch, Birgit; Wiegand, Susanna

doi:10.1111/j.1651-2227.2010.02119.x

Cited by 16 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glucose levels were not available. In line with previous studies (van Vliet et al, 2009;Dannemann et al, 2011), we observed a higher odds of clustering values are odds ratios (95% CI) that reflect the risk of clustering cardiovascular risk factors per different childhood ethnicity groups. Crude models are adjusted for child's age at visit, sex.…”

Section: Cardiovascular Risk Factorssupporting

confidence: 91%

Early origins of ethnic disparities in cardiovascular risk factors

Gishti

Gaillard

Felix

et al. 2015

Preventive Medicine

View full text Add to dashboard Cite

Section: Cardiovascular Risk Factorssupporting

confidence: 91%

Early origins of ethnic disparities in cardiovascular risk factors

Gishti

Gaillard

Felix

et al. 2015

Preventive Medicine

View full text Add to dashboard Cite

“…51 Obese youth are twice as likely to have hypertension (for SBP > 140, OR = 2.24; CI, 1.46 – 3.45: P < 0.001, and for DBP > 90, OR = 2.10: CI, 1.063–4.17, P = 0.03) 52 and high blood pressure has been documented as a co-morbidity of obesity in minority and immigrant samples as well. 28,45,53 One study of 1053 patients from an obesity outpatient clinic in Germany found that rates of metabolic syndrome were significantly higher among Turkish patients (40.4%) compared to Germans (27.3%; p = 0.02). 53 …”

Section: Resultsmentioning

confidence: 99%

“…28,45,53 One study of 1053 patients from an obesity outpatient clinic in Germany found that rates of metabolic syndrome were significantly higher among Turkish patients (40.4%) compared to Germans (27.3%; p = 0.02). 53 …”

Section: Resultsmentioning

confidence: 99%

“…122 Other researchers use the International Obesity Task Force guidelines 123 or guidelines specific to the country the research is being conducted. 53 Some investigators use adult overweight (BMI>25) and obesity (BMI>30) guidelines. 73 Although the merits of each of these classification systems can be debated, the lack of consistency among BMI thresholds used by researchers makes consolidating evidence across studies problematic and a limitation of the literature as a whole.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Childhood Obesity: A Review of Increased Risk for Physical and Psychological Comorbidities

Pulgarón

2013

Clinical Therapeutics

554

385

View full text Add to dashboard Cite

Background Worldwide estimates of childhood overweight/obesity are as high as 43 million and rates continue to increase each year. Researchers have taken interest in the childhood obesity epidemic and the impact of this condition across health domains. The consequences of childhood and adolescent obesity are extensive, including both medical and psychosocial comorbidities. Objective The purpose of this review was to consolidate and highlight the recent literature on the comorbidities associated with childhood obesity, both nationally and internationally. Methods PubMed and PsychINFO searches were conducted on childhood obesity and co-morbidities. Results The initial search of the terms “obesity” and “comorbidity” yielded over 5000 published articles. Limits were set to include studies on children and adolescents that were published in peer-reviewed journals from 2002 to 2012. These limits narrowed the search to 938. Review of those articles resulted in 79 that are included in this review. The major medical comorbidities associated with childhood obesity in the current literature are metabolic risk factors, asthma, and dental health issues. Major psychological comorbidities include internalizing and externalizing disorders, ADHD, and sleep problems. Conclusions The high prevalence rates of childhood obesity have resulted in extensive research in this area. Limitations to the current childhood obesity literature include differential definitions of weight status and cut off levels for metabolic risk factors across studies. Additionally, some results are based on self-report of diagnoses rather than chart reviews or physician diagnosis. Even so, there is substantial support for metabolic risk factors, internalizing disorders, ADHD, and decreased health related quality of life as comorbidities to obesity in childhood. Additional investigations on other diseases and conditions that may be associated with childhood obesity are warranted and intervention research in this area is critical.

show abstract

“…Obesity is known to be associated with premature mortality from vascular disease. Prevalences of metabolic syndrome in obese children vary from 14·5% in the UK to 32·3% in a German multiethnic cohort, to 39% in a Turkish cohort . Numbers in the US tend to be higher, with 38·7% in moderately obese children and 49·7% in severely obese children, although some of these differences might reflect differences in the definitions used for metabolic syndrome.…”

Section: Introductionmentioning

confidence: 98%

Is there sufficient evidence to consider the use of 11β‐hydroxysteroid dehydrogenase type 1 inhibition in children?

Fürst‐Recktenwald

Dörr²,

Quinkler

et al. 2012

Clinical Endocrinology

View full text Add to dashboard Cite

SummaryManifestations of the metabolic syndrome [obesity, dyslipidaemia, hypertension, blood glucose derangements including prediabetes or type 2 diabetes mellitus (T2DM)] in juvenile populations are becoming increasingly prevalent throughout the world and are at the point of being a global public health concern. Derangements in cortisol regeneration seem to be involved in the pathophysiology. Treatment with selective 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitors could be a therapeutic strategy in paediatric patients with manifestations of the metabolic syndrome. Based on preclinical and clinical data regarding development of the 11β-HSD1 enzyme, it appears that maturation occurs within the first year of life. Different changes in biomarkers for assessing the efficacy and safety of 11β-HSD1 inhibitors are to be expected in paediatric patients compared to adults, reflecting differences in metabolism. The effect of 11β-HSD1 treatment in children on bone differentiation and development as well as adrenocorticotropic hormone (ACTH), circulating and local cortisol tissue concentrations, androgens and respective stress response is not yet known. Based on current literature, the concept of inhibition of 11β-HSD1 is considered a potentially effective mean to regulate local cortisol levels in the paediatric population, and 11β-HSD1 inhibitors may provide a valuable target and treatment option for the metabolic syndrome in paediatric patients. However, the uncertainty over effects on the developing skeleton combined with mild increases in adrenal androgen levels raises potential concerns regarding growth as well as onset of puberty as to their future use in children. Future clinical studies are needed to thoroughly assess the risks and benefits of this new class of drugs in the paediatric population.

show abstract

Ethnicity and comorbidities in an overweight and obese multiethnic childhood cohort in Berlin

Cited by 16 publications

References 22 publications

Early origins of ethnic disparities in cardiovascular risk factors

Early origins of ethnic disparities in cardiovascular risk factors

Childhood Obesity: A Review of Increased Risk for Physical and Psychological Comorbidities

Is there sufficient evidence to consider the use of 11β‐hydroxysteroid dehydrogenase type 1 inhibition in children?

Contact Info

Product

Resources

About